Lund, Sweden, February 4th, 2010 -- CMA Microdialysis AB (”CMA”) today announced that is has signed an agreement to acquire the
assets of DiLab i Lund AB, for an undisclosed cash amount. DiLab is the pioneer and market leader in
the field of Automated Blood Sampling (ABS) providing solutions to the Life Science Industry for over
20 years. The acquisition is expected to complement CMA’s portfolio of leading research solutions for
use in drug discovery and development.
DiLab’s AccuSampler® systems are used in preclinical research in major pharmaceutical companies,
contract research organizations and universities all over the world. DiLab was established in 1984
with headquarters in Lund, Sweden. Customers are supported through a direct European sales force,
subsidiary in the US and distributors in the Asian counties.
CMA is the industry leader providing microdialysis solutions for in vivo sampling and monitoring of
tissues and organs. CMA’s unique products are used across the globe in early drug discovery, PK/PD,
clinical research and routinely for monitoring critically ill patients in intensive care.
Many decisions in drug development and medical practice are based on measuring blood
concentrations of endogenous and exogenous molecules. Yet most biochemical and pharmacological
events take place in the tissues. By combining the local advantages of microdialysis sampling in tissue
with the benefits of systemic ABS, drug development can potentially become more cost-effective and
lead to better understanding of exposure-response relationships that ultimately will help to develop
better drug products.
Philip Siberg, CEO of CMA Microdialysis commented, "I am delighted to join forces with the market
leader within ABS. By combining our leading product portfolios, know-how and customer service we
can offer a complete solution for the pharmaceutical research industry."
For more info, please contact Philip Siberg on +46 70 7906734 or email@example.com
CMA Microdialysis (“CMA”) is a Swedish medical device and life science company founded in 1984. Unique and market
leading solutions are developed, produced and sold to clinicians and researchers to enable optimized patient care and
accelerated drug development. CMA’s complete line of instruments, consumables and computer software are used globally
by universities, hospitals and pharmaceutical companies as unique tools for in vivo sampling and monitoring of organs and
blood. The core competence lies within solutions based on the Microdialysis technique and products are produced in
Sweden under ISO 13485 and according to FDA standards. With a highly specialized and skilled staff, consumables are
manufactured in a Class 8 clean room environment.
The head office is located outside Stockholm, Sweden, with subsidiary in USA. CMA has distributors across the globe,
responsible for local sales, service and support. CMA is primarily owned by Investor AB and Bure AB, both leading Swedish
industrial holding companies listed on the Stockholm Stock Exchange. For more info, see www.microdialysis,se